Article
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
All News
Article
Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.
Dr. John Cush
Tweet
Taiwan population study shows increased all-cause mortality for psoriasis patients (HR 1.16; 1.13-1.19) vs. general population. https://t.co/p09mXTfXPw https://t.co/UVK3GMMmip
Dr. John Cush
Tweet
Study of 247 consecutive PsA pts shows that two-thirds (63.15%) had poor sleep quality. Poorer sleep was assoc w/ being female, higher joint counts, greater peripheral and axial disease activity, but fatigue & anxiety most explained poor sleep quality https://t.co/RTZqxtyIu9 https://t.co/OVtTQkFirD
Dr. John Cush
Tweet
Secukinumab retention in PsA: Study of 170 pts, 13% B27+, most w/ peripheral arthritis &70% on 150 mg/mo. Median retention 636 days. Peripheral arthritis was a predictor of better retention (HR 0.424). https://t.co/aZD9qD0jxm https://t.co/FlqRlcAZd1
Dr. John Cush
Tweet
The Atlantic has published an insightful article on "Brain Fog", especially as a Long Covid consequence (IMHO: Brain fogs primary cause is poor sleep, fibromyalgia, chronic fatigue - but can be complication to primary CNS events) https://t.co/SlwzRDSVSf https://t.co/qrBvV5oyUA
Dr. John Cush
Tweet
Doctor Appointment Wait Times are Up
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
https://t.co/oJkLRzRR1y https://t.co/8zy0LgC7dt
Dr. John Cush
Tweet
TYK2 Inhibitor FDA Approved for Psoriasis
BMS made a mega bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while auctioning off Celgene’s top-selling Otezla to Amgen for $13.4 billion
https://t.co/wPN62jBIvL https://t.co/Cj6svOoiaJ
A Omar
Tweet
I created an online version of the Modified Rodnan Skin Score (mRSS) to make it easier to calculate
References mentioned below tool:
https://t.co/5Us3usCTsC
@SindhuJohnson5 @Janetbirdope
#scleroderma #rheum #rheumatology
Charlie Clements
Tweet
Nice table from the Poddubny et al., (2021) study which looks at some of the different characteristics between Axial SpA vs Axial PsA.
Axial PsA tends to have;
- Less frequent IBP
- Less HLAB27 +‘ve
- More frequent C-spine involvement https://t.co/XXQKBSfSQq
Leonard Calabrese
Tweet
In your RHEUMATOLOGY practice how often are you seeing #LongCovid (new fatigue,brainfog,breathless etc) in your immune dis pts with COVID ( i.e. > 1 month) @CCalabreseDO @jeffsparks @zach_wallace_md @philipcrobinson @JYazdanyMD @alhkim @RheumNow @EBRheum @rheum_cat @AWIRGROUP
Dr. John Cush
Tweet
The ACR is developing a new clinical practice guideline for systemic autoimmune rheumatic disease with interstitial lung disease (ILD). The Call for Public Comment is open until September 29, 2022. https://t.co/UxXDbGEQlh https://t.co/zGoBpbKLTC
Dr. John Cush
Tweet
A longitudinal study of 506 ANCA-associated vasculitis (AAV) pts showed pts w/ negative ANCA serologies within 180 days of induction had signif lower risk of relapse (HR 0.55; 0.38 to 0.81) but not for ESRD or death within 5 years. https://t.co/Dn8GGXnSDi https://t.co/C73hG9T7Au
Dr. John Cush
Tweet
Immunosuppresive (IST; MMF or AZA) withdrawl in 96 stable Lupus Nephritis pts also on HCQ. After 2 years, Relapse occurred in 12.5% w/ IST continued & 27.3% with IST D/C (Not noninferior). Less Severe SLE flares (renal & extrarenal) w/ IST continuation https://t.co/XWmJpkqhG9 https://t.co/gYM24QIiYz
Dr. John Cush
Tweet
COVID Outcomes in Dermatomyositis
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
https://t.co/nlCVHt3XeS https://t.co/Bhc47k7rMD
Dr. John Cush
Tweet
Does Fibromyalgia Need B12?
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news.
https://t.co/ztDVHfGegM https://t.co/ux4F0UIIld
Dr. John Cush
Tweet
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/xchK5ETmg3 https://t.co/F9klsUE5er
Dr. John Cush
Tweet
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/o9sO5WQmcq https://t.co/6RrrKzu41p
Dr. John Cush
Tweet
Voclosporin Efficacy and Safety in Lupus Nephritis
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
https://t.co/WqQ7wdzmCc https://t.co/uxFb6Nbdgi
Dr. John Cush
Tweet
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/wCyZjRbWe8 https://t.co/U0LlDnuNtZ
